Clinical trial
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at…
NCT00303316 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00303316 |
|---|---|
| Title | Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants |
| Official title | Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B |
| Intervention type | Biological |
| Interventions | DTaP-IPV//PRP~T combined vaccine |
| Enrollment | 458 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Mar 16, 2006 |
| Last update posted | Feb 22, 2013 |
| Countries | Argentina |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: